Table 1 Patient demographics and clinical characteristics.
From: Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors
Patient characteristic | Safety population | Total N = 31 | ||
|---|---|---|---|---|
50 mg n = 3 | 100 mg n = 16 | 200 mg n = 12 | ||
Age, years | ||||
Mean (SD) | 68.0 (6.6) | 55.5 (15.1) | 59.7 (10.9) | 58.3 (13.2) |
Sex, n (%) | ||||
Male | 2 (67) | 4 (25) | 3 (25) | 9 (29) |
Female | 1 (33) | 12 (75) | 9 (75) | 22 (71) |
Ethnicity | ||||
Not Hispanic or Latino | 3 (100) | 15 (94) | 9 (75) | 27 (87) |
Hispanic or Latino | 0 | 1 (6) | 3 (25) | 4 (13) |
Race, n (%)a | ||||
White | 3 (100) | 14 (88) | 10 (83) | 27 (87) |
Asian | 0 | 2 (13) | 1 (9) | 3 (10) |
Primary tumor type, n (%) | ||||
Colon/rectum | 0 | 2 (13) | 4 (33) | 6 (19) |
Pancreas | 1 (33) | 2 (13) | 1 (8) | 4 (13) |
Ovary | 1 (33) | 0 | 1 (8) | 2 (6) |
Bladder | 0 | 0 | 1 (8) | 1 (3) |
Breast | 0 | 1 (6) | 0 | 1 (3) |
Cervix | 0 | 1 (6) | 0 | 1 (3) |
Cholangiocarcinoma in gallbladder | 0 | 1 (6) | 0 | 1 (3) |
Desmoplastic small round cell tumor | 0 | 1 (6) | 0 | 1 (3) |
Epithelioid hemangioendothelioma | 0 | 0 (0) | 1 (8) | 1 (3) |
Gastric | 0 | 1 (6) | 0 | 1 (3) |
Head and neck | 0 | 1 (6) | 0 | 1 (3) |
Liver | 1 (33) | 0 (0) | 0 | 1 (3) |
Malignant neoplasm of parotid gland | 0 | 1 (6) | 0 | 1 (3) |
Malignant perivascular epithelioid cell neoplasm | 0 | 1 (6) | 0 | 1 (3) |
Melanoma | 0 | 1 (6) | 0 | 1 (3) |
Mucoepidermoid cancer of parotid | 0 | 0 (0) | 1 (8) | 1 (3) |
Nasopharynx carcinoma | 0 | 1 (6) | 0 (0) | 1 (3) |
Non-small cell lung | 0 | 0 (0) | 1 (8) | 1 (3) |
Osteosarcoma | 0 | 1 (6) | 0 | 1 (3) |
Pleomorphic adenoma | 0 | 1 (6) | 0 (0) | 1 (3) |
Prostate | 0 | 0 | 1 (8) | 1 (3) |
Uterine perivascular epithelioid cell tumor | 0 | 0 | 1 (8) | 1 (3) |
MTAP loss, n (%) | – | 2 (13) | 4 (33) | 6 (19) |
Time since diagnosis, days Median (min, max) | 735 (685, 1259) | 596 (359, 3487) | 923 (321, 2898) | 765 (321, 3487) |
